Cell and gene therapies have become invaluable modalities in the medicine toolkit. Following recent safety concerns with AAV vector technology, experts will look increasingly toward new vectors and delivery methods. In terms of patient access, political action on drug pricing casts the cost considerations of CGT in a new light. Manufacturing innovations can reduce costs to some degree, but payer incentives within the broader healthcare industry must be aligned with these often one-and-done treatments. Building on a panel discussion featured at BIO 2025 about the innovation needed in manufacturing processes, this session will focus on how those advances must come hand in hand with improvements across the entirety of the cell and gene therapy ecosystem - from the design of the therapies themselves to their delivery to patients.